Where does stocks-llm's data on MEDP come from?

Fundamentals and prices come from Finnhub, as of 2026-07-10; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

← stocks-llm Find companies like MEDP →

Medpace (MEDP)

Health Care

A leading full-service clinical contract research organization (CRO) providing Phase I-IV development services to biotech, pharma, and medical device companies.

View SEC filings Website Yahoo Finance Find companies like MEDP → Ask about MEDP →

What Medpace does

Medpace is one of the world's leading clinical contract research organizations (CROs) solely focused on providing outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company offers comprehensive Phase I-IV clinical trial services across all major therapeutic areas, with particular strength in Oncology, Metabolic, Cardiology, Antiviral/Anti-infective, and Central Nervous System disorders. Medpace differentiates itself through its disciplined full-service operating model, therapeutic expertise, proprietary technology platform (ClinTrak), and focus on serving small and mid-sized biopharmaceutical companies with timely, high-quality, and cost-effective clinical development solutions.

Themes: ["Clinical trial outsourcing / CRO services","Oncology drug development","Metabolic disease therapeutics","Cardiology clinical trials","Antiviral and anti-infective development","Central nervous system (CNS) therapeutics","Patient recruitment and retention","Regulatory compliance and medical writing"]

Fundamentals

Price$535.50 as of 2026-07-09 close
Market cap$15.2B as of 2026-07-10
1-year return+66.8% as of 2026-07-09 close
P/E33.00 as of 2026-07-10
Net margin+17.2% as of 2026-07-10
Gross margin+29.1% as of 2026-07-10
ROE+120.9% as of 2026-07-10
Debt / equity0.00 as of 2026-07-10
Revenue growth (YoY)+24.2% as of 2026-07-10
Revenue CAGR (3y)+20.1% SEC XBRL
Beta1.15 as of 2026-07-10

Ask why MEDP looks like this →

Key risks (from latest filing)

["Dependence on customer spending in biotechnology and pharmaceutical industries, which is cyclical and sensitive to market conditions, funding availability, and regulatory decisions","Regulatory and compliance risks related to clinical trial operations, including adherence to GCP, ICH guidelines, and varying international regulations across multiple jurisdictions","Key customer concentration risk: revenue from a limited number of large biopharmaceutical and pharmaceutical clients represents a material portion of total revenue"]

See MEDP's biggest risks from its latest 10-Q →

Competitors & peers

IQVIA Holdings (IQV)
Syneos Health (SYNH)
Parexel International (PRXL)
Charles River Laboratories (CRL)
Covance (part of LabCorp)
Envigo
PharmaGo

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.